Payment overview · 2025
General Payments
$738.82
44 reported records · 16 companies
Healthcare provider profile · identity verified
Mitchel Norton, DO
Allopathic & Osteopathic Physicians|Family Medicine · CASSVILLE, MO · NPI 1073047957
Verified facts
What the public records show
CMS Open Payments records show Mitchel Norton, DO received $738.82 in general payments during 2025 across 44 reported records.
PFIZER INC. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.23 | 18.7% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $103.81 | 14.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.58 | 11.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.89 | 9.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.14 | 8.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $49.82 | 6.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.93 | 6.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.53 | 4.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.44 | 4.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.33 | 3.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.10 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.92 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.39 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.25 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.49 | 2.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $9.97 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $738.82 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $118.71 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $103.81 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $103.76 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.93 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.93 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.93 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $9.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $9.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 106 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 336 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
143 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
106 | 106 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
336 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 954 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 922 | 296 |
| Levothyroxine Sodium | Levothyroxine Sodium | 876 | 253 |
| Gabapentin | Gabapentin | 748 | 170 |
| Omeprazole | Omeprazole | 746 | 214 |
| Tramadol Hcl | Tramadol Hcl | 705 | 123 |
| Losartan Potassium | Losartan Potassium | 601 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 506 | 156 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 493 | 74 |
| Alprazolam | Alprazolam | 475 | 72 |
| Lisinopril | Lisinopril | 455 | 152 |
| Pregabalin | Pregabalin | 441 | 74 |
| Lorazepam | Lorazepam | 433 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 421 | 132 |
| Oxycodone Hcl | Oxycodone Hcl | 405 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 381 | 115 |
| Metformin Hcl | Metformin Hcl | 362 | 103 |
| Potassium Chloride | Potassium Chloride | 359 | 99 |
| Furosemide | Furosemide | 358 | 109 |
| Donepezil Hcl | Donepezil Hcl | 351 | 99 |
| Eliquis | Apixaban | 336 | 65 |
| Trazodone Hcl | Trazodone Hcl | 335 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 89 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 298 | 87 |
| Fluticasone Propionate | Fluticasone Propionate | 294 | 90 |
| Meloxicam | Meloxicam | 276 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 264 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 72 |
| Montelukast Sodium | Montelukast Sodium | 232 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 192 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 49 |
| Famotidine | Famotidine | 190 | 45 |
| Morphine Sulfate Er | Morphine Sulfate | 184 | 26 |
| Clonazepam | Clonazepam | 169 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 169 | 30 |
| Allopurinol | Allopurinol | 165 | 43 |
| Simvastatin | Simvastatin | 164 | 46 |
| Carvedilol | Carvedilol | 160 | 48 |
| Diazepam | Diazepam | 151 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 46 |
| Glipizide | Glipizide | 150 | 45 |
| Alendronate Sodium | Alendronate Sodium | 146 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 40 |
| Sertraline Hcl | Sertraline Hcl | 145 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 143 | 27 |
| Prednisone | Prednisone | 131 | 97 |
| Ozempic | Semaglutide | 127 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 123 | 26 |
| Ezetimibe | Ezetimibe | 121 | 35 |
| Mirtazapine | Mirtazapine | 117 | 34 |
| Ondansetron Odt | Ondansetron | 113 | 53 |
| Spironolactone | Spironolactone | 112 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 111 | 25 |
| Metformin Hcl Er | Metformin Hcl | 109 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 108 | 34 |
| Jardiance | Empagliflozin | 108 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 106 | 106 |
| Azelastine Hcl | Azelastine Hcl | 106 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 30 |
| Atenolol | Atenolol | 104 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 103 | 39 |
| Baclofen | Baclofen | 100 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 24 |
| Warfarin Sodium | Warfarin Sodium | 89 | 21 |
| Bupropion Xl | Bupropion Hcl | 88 | 26 |
| Primidone | Primidone | 88 | 23 |
| Diclofenac Sodium Er | Diclofenac Sodium | 86 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 84 | 20 |
| Clonidine Hcl | Clonidine Hcl | 81 | 29 |
| Lovastatin | Lovastatin | 78 | 24 |
| Finasteride | Finasteride | 77 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 77 | 17 |
| Celecoxib | Celecoxib | 75 | 17 |
| Chlorthalidone | Chlorthalidone | 75 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 71 | 22 |
| Temazepam | Temazepam | 70 | 11 |
| Xarelto | Rivaroxaban | 70 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 20 |
| Linzess | Linaclotide | 67 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 23 |
| Memantine Hcl | Memantine Hcl | 65 | 12 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Azithromycin | Azithromycin | 63 | 58 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 61 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 61 | 15 |
| Cefdinir | Cefdinir | 58 | 41 |
| Meclizine Hcl | Meclizine Hcl | 58 | 17 |
| Promethazine Hcl | Promethazine Hcl | 58 | 14 |
| Glipizide Er | Glipizide | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 22 |
| Propranolol Hcl | Propranolol Hcl | 57 | 18 |
| Januvia | Sitagliptin Phosphate | 56 | 14 |
| Rexulti | Brexpiprazole | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 51 |
| Ibuprofen | Ibuprofen | 54 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 13 |
| Sucralfate | Sucralfate | 50 | suppressed |
| Estradiol | Estradiol | 49 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Carisoprodol | Carisoprodol | 48 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 47 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Aripiprazole | Aripiprazole | 43 | 11 |
| Fluconazole | Fluconazole | 42 | 30 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 11 |
| Nitroglycerin | Nitroglycerin | 41 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 13 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | suppressed |
| Nystatin | Nystatin | 39 | 22 |
| Topiramate | Topiramate | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 15 |
| Naproxen | Naproxen | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Oxycontin | Oxycodone Hcl | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 14 |
| Fentanyl | Fentanyl | 37 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Trospium Chloride | Trospium Chloride | 36 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Felodipine Er | Felodipine | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Savella | Milnacipran Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Digoxin | Digoxin | 13 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Dyrenium | Triamterene | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $738.82 · 44 records | PFIZER INC. | ABRYSVO, BEXSERO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, GARDASIL 9, JARDIANCE, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, VAXELIS, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error